Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens

Lancet

Volumn 351, Issue 9103, 1998, Pages 623-628

  Dantal, Jacques ^a   Hourmant, Maryvonne ^a   Cantarovich, Diego ^a   Giral, Magali ^a   Blancho, Gilles ^a   Dreno, Brigitte ^a   Soulillou, Jean Paul ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CANCER; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SKIN CANCER; SURVIVAL; SYMPTOM;

EID: 0032574187     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)08496-1     Document Type: Article

References (30)

1. 1 The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1986; 314: 1219-25.
2. 2 Bennett WM, De Mattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-100.
3. 3 Sheil AGR, Disney APS, Mathew TH, et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383-84.
4. 4 Hourmant M, Taupin JL, Lemergie D, et al. Azathioprine-cyclosporine A (CyA) double therapy versus CyA alone after the first rejection episode in kidney-transplanted patients under CyA: a randomized study. Tranplant Int 1989; 2: 113-16.
5. 5 Opelz G. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 1994; 58: 443-46.
6. 6 Hourmant M, Le Mauff B, LeMeur Y, et al. Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation: a pilot study. Transplantation 1994; 58: 377-80.
7. 7 Dantal J, Ninin E, Hourmant M, et al. Anti-CD4 MoAb therapy in kidney transplantation: a pilot study in early prophylaxis of rejection. Transplantation 1996; 62: 1502-06.
8. 8 Soulillou JP, Cantarovich D, Lemauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulins for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175-82.
9. 9 Burcke JF, Pirsch JD, Ramos EL, et al. A multicenter four year retrospective study in renal transplant recipients treated with cyclosporine: evidence for long term efficacy and safety. N Engl J Med 1994; 331: 358-63.
10. 10 Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-22.
11. 11 European Multicenter Trial Group. Cyclosporin in cadaveric renal transplantation: 1 year follow-up of a multicentre trial. Lancet 1983; ii: 986-89.
12. 12 Kasiske BL, Heim-Duthoy KL, Ma JZ. Elective cyclosporine withdrawal after renal transplantation: a metaanalysis. JAMA 1993; 269: 395-400.
13. 13 Lindholm A, Ohlman S, Albrechtsen D, et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56: 307-15.
14. 14 Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Tearaski PI, Cecka JM, eds. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1994: 99-109.
15. 15 Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-16.
16. 16 Kovarik JM, Mueller EA, Van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658-63.
17. 17 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-37.
18. 18 Vincenti F, Laskow DA, Neylan JF, et al. One-year follow-up of an open-label trial of FK 506 for primary kidney transplantation. Transplantation 1996; 61: 1576-81.
19. 19 Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997; 29: 36-41.
20. 20 Morris RE. Beware: shifting paradigms ahead. Lancet 1996; 348 (suppl II): II26.
21. 21 Dilling MB, Dias P, Shapiro DN, et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the insulin like growth factor receptor. Cancer Res 1994; 54: 903-08.
22. 22 Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994; 57: 568-73.
23. 23 Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS scientific renal transplant registry at three years - early events affecting transplant success. Transplantation 1992; 53: 59-64.
24. 24 London NJ, Farmery SM, Will EJ, et al. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403-06.
25. 25 Blohmé I, Larkö O. Premalignant and malignant skin lesions in renal transplant patients. Transplantation 1984; 37: 165-67.
26. 26 Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996; 46: 1607-12.
27. 27 West M, Sutherland D, Matas A. Kidney transplant recipients who die with functioning grafts. Transplantation 1996; 62: 1019-30.
28. 28 Morris JDH, Eddleston ALWF, Crook T. Viral infection and cancer. Lancet 1995; 346: 754-58.
29. 29 Buccianti G, Ravasi B, Cresseri D, et al. Cancer in patients on renal replacement therapy in Lombardy, Italy. Lancet 1996; 347: 59-60.
30. 30 Stewart T, Tsai SCJ, Grayson H, et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995; 346: 796-98.